Literature DB >> 18414185

Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.

Nirav Desai1, Jameel Sajjad, William H Frishman.   

Abstract

Urotensin II was first identified over 30 years ago as a potent vasoconstrictor, and the identification of its receptor in the heart, lungs, blood vessels, and brain have made it a potential target for human pharmacotherapy. Current research would suggest that urotensin II plays a major role in the pathophysiology of various cardiovascular disease entities. This article discusses the biologic effects of urotensin under normal and pathophysiologic conditions, and reviews the research experiences with synthetic urotensin blockers in the treatment of various cardiovascular illnesses.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18414185     DOI： 10.1097/CRD.0b013e31815c8048

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN： 1061-5377            Impact factor:   2.644


  7 in total

1.  In vitro siRNA-mediated knockdown of the UT receptor: implications of density on the efficacy of a range of UT ligands.

Authors:  Benjamin D Hunt; Leong L Ng; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-06       Impact factor: 3.000

2.  Urotensin II in invertebrates: from structure to function in Aplysia californica.

Authors:  Elena V Romanova; Kosei Sasaki; Vera Alexeeva; Ferdinand S Vilim; Jian Jing; Timothy A Richmond; Klaudiusz R Weiss; Jonathan V Sweedler
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

3.  Potential Clinical Implications of the Urotensin II Receptor Antagonists.

Authors:  Philip Tsoukas; Emilie Kane; Adel Giaid
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

4.  De novo deletions and duplications of 17q25.3 cause susceptibility to cardiovascular malformations.

Authors:  F J Probst; R A James; L C Burrage; J A Rosenfeld; T P Bohan; C H Ward Melver; P Magoulas; E Austin; A I A Franklin; M Azamian; F Xia; A Patel; W Bi; C Bacino; J W Belmont; S M Ware; C Shaw; S W Cheung; S R Lalani
Journal:  Orphanet J Rare Dis       Date:  2015-06-14       Impact factor: 4.123

5.  The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF-κB pathways in LPS-stimulated Kupffer cells.

Authors:  Liang Ming Liu; Dong Yu Liang; Chang Gen Ye; Wen Juan Tu; Tong Zhu
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

6.  Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF-κB pathway in ALF mice.

Authors:  Dong-yu Liang; Liang-ming Liu; Chang-gen Ye; Liang Zhao; Fang-ping Yu; De-yong Gao; Ying-ying Wang; Zhi-wen Yang; Yan-yan Wang
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

7.  IRF3 is an important molecule in the UII/UT system and mediates immune inflammatory injury in acute liver failure.

Authors:  Liang-Ming Liu; Wen-Juan Tu; Tong Zhu; Xiao-Ting Wang; Zhi-Li Tan; Huan Zhong; De-Yong Gao; Dong-Yu Liang
Journal:  Oncotarget       Date:  2016-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.